Therefore, we believe that infection with different high-risk HPV types leads to differences in the sensitivity of patients with CC to PD-1/PD-L1 immunotherapy, which provides a reference for individualized and specific clinical treatment and a basis for the development of more effective immune checkpoint inhibitors. The gene discussed is PDCD1; the disease is infection.